Adenovirus decision: Little fallout seen

Last week's announcement by the Cystic Fibrosis Foundation that it "has suspended recruitment for CF gene therapy studies using the adenovirus vector, until more information on the vector's safety can be obtained", may not have much effect either on trials in CF or on the trials of adenoviral vectors in gene therapies for other diseases.

The foundation's action came amid other calls to improve oversight of gene therapy in the wake of the death of a University of Pennsylvania patient in a study involving an adenovirus vector (see today's BioCentury, the Bernstein Report on BioBusiness). ...